Jack A Schalken received his PhD at the science faculty of the University of Nijmegen in 1987, on a topic related to differential gene expression in cancer. He initiated the urological research program at the UMC St Radboud from 1986 onwards. His main focus is on the molecular life sciences aspects of GU pathologies, and his laboratory is housed in the Nijmegen Center for Molecular Life Sciences (NCMLS) at Nijmegen campus, integrating groups using similar approaches to combat various diseases. He was appointed full professor of oncology at the University of Utrecht veterinary school (1996), which he combined with his Nijmegen position. He was appointed professor of experimental urology in 2001 at the Nijmegen University. Prof Schalken has (co) authored ~ 253 peer reviewed papers, ~ 55 chapters and is often invited as lecturer.

Publications

• Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy


• Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results


• Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer


• Molecular PCA3 diagnostics on prostatic fluid


• Molecular markers for prostate cancer


• The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance


• Validation of molecular targets in prostate cancer


• Molecular prostate cancer pathology: current issues and achievements


• New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene


• DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer


• DD3(PCA3), a very sensitive and specific marker to detect prostate tumors


• Molecular diagnostics and therapy of prostate cancer: new avenues